Christopher Cogle, M.D.

Christopher R Cogle, M.D.

(352) 733-0972

Request an Appointment

Publications

Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
British journal of haematology
2020

Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
International journal of laboratory hematology
2020

RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.
Cell stem cell
2020

Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes.
Leukemia research
2020

Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
Future oncology (London, England)
2020

Identification of Unique mRNA and miRNA Expression Patterns in Bone Marrow Hematopoietic Stem and Progenitor Cells After Trauma in Older Adults.
Frontiers in immunology
2020

Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.
International journal of molecular sciences
2020

Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia.
Cancers
2020

Finding incident cancer cases through outpatient oncology clinic claims data and integration into a state cancer registry.
Cancer causes & control : CCC
2020

Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients.
Hematology/oncology and stem cell therapy
2020

Clinical Application of Computational Methods in Precision Oncology: A Review.
JAMA oncology
2020

Cancer in the Time of Coronavirus: A Call for Crisis Oncology Standards of Care.
Healthcare (Basel, Switzerland)
2020

Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Leukemia research
2019

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.
Leukemia research
2019

Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
Clinical lymphoma, myeloma & leukemia
2019

Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.
Leukemia research
2019

Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2019

HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice.
Cancer cell
2019

Continuous Rural-Urban Coding for Cancer Disparity Studies: Is It Appropriate for Statistical Analysis?
International journal of environmental research and public health
2019

Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.
Leukemia research
2019

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Blood advances
2019

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Cancers
2019

Using Social Media to Assess Care Coordination Goals and Plans for Leukemia Patients and Survivors
Translational Behavioral Medicine
2018

Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Journal of clinical apheresis
2018

Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.
Clinical cancer research : an official journal of the American Association for Cancer Research
2018

Functional genomic landscape of acute myeloid leukaemia.
Nature
2018

Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
Journal of medicinal chemistry
2018

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
Leukemia research
2018

CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
Blood
2018

CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation.
Leukemia research
2018

CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.
Leukemia research
2018

The role and clinical implications of the endosteal niche and osteoblasts in regulating leukemia.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
2017

The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.
The oncologist
2017

Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2.
Leukemia research
2017

Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1β- and IL-6-Related Impairment of Bone Marrow Function.
Circulation research
2017

Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
Blood cancer journal
2017

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.
Molecular therapy oncolytics
2017

Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Leukemia research
2017

Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.
Leukemia research
2017

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes.
Current hematologic malignancy reports
2017

Association of breast carcinoma growth with a non-canonical axis of IFNγ/IDO1/TSP1.
Oncotarget
2017

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.
Viruses
2016

Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.
Cell transplantation
2016

Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells.
Cytotherapy
2016

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.
Leukemia
2016

Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Clinical transplantation
2016

Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.
Expert review of pharmacoeconomics & outcomes research
2016

Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
BMC cancer
2016

Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
Leukemia & lymphoma
2016

Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (WISE-CVD).
Atherosclerosis
2016

Chemosensitizing AML cells by targeting bone marrow endothelial cells.
Experimental hematology
2016

Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial.
American heart journal
2016

Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells.
Hypertension (Dallas, Tex. : 1979)
2016

An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats.
International journal of cardiology
2016

Acute myeloid leukemia in the vascular niche.
Cancer letters
2016

A new model to predict remission status in AML patients based on day 14 bone marrow biopsy.
Leukemia research
2016

Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians.
Transfusion
2015

Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome.
Leukemia research reports
2015

Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease.
Biochemical and biophysical research communications
2015

Poor Peripheral Blood Stem Cell Mobilization Correlates With Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Biology of Blood and Marrow Transplantation
2015

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
PloS one
2015

Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
The oncologist
2015

Incidence and Burden of the Myelodysplastic Syndromes.
Current hematologic malignancy reports
2015

Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
Leukemia research
2015

Bone marrow niche in the myelodysplastic syndromes.
Leukemia research
2015

Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial.
Circulation research
2015

Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study.
Clinical Medicine Insights. Oncology
2014

Response to letter regarding article, "a detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b and clonogenic capacity as biomarkers for clinical outcomes".
Circulation research
2014

Radiation alone for solid tumors and the questionable development of therapy-related myelodysplastic syndromes.
Journal of the National Cancer Institute
2014

Myelodysplastic Syndromes Management and Treatment: a Conceptual Framework
Haematologica
2014

Mapping hematopoiesis in a fully regenerative vertebrate: the axolotl.
Blood
2014

High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment.
Leukemia research
2014

Functional integration of acute myeloid leukemia into the vascular niche.
Leukemia
2014

Fishing for myelodysplastic syndromes finds uncaptured cases by state cancer registries: Need for more resources.
Cancer
2014

Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.
Circulation research
2014

Angiotensin II Regulates Hematopoietic Stem Cell Proliferation, Differentiation and Engraftment Efficacy
Experimental Hematology
2014

A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
Human Gene Therapy
2014

Variable and Decreased Clonogenic Activity of Autologous Bone Marrow in Cell Therapy Patients With Ischemic Heart Disease, and Cd34 as a Biomarker for Clinical Outcomes: Results From the Cardiovascular Cell Therapy Research Network (Cctrn)
Circulation
2013

The Nhlbi Time Trial: One-Year Results
Circulation
2013

PARP1 is required for chromosomal translocations.
Blood
2013

Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2.
Journal of the National Cancer Institute
2013

A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials.
Current atherosclerosis reports
2013

Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells.
PloS one
2012

Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells By Depolymerizing the Microtubule Cytoskeleton
Blood
2012

Underreporting of myeloid malignancies by United States cancer registries.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2012

The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
The American journal of pathology
2012

The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarction: the Nhlbi and Cctrn Time Trial
Circulation
2012

Single Versus Tandem Autologous Stem Cell Transplantation (Asct) for Multiple Myeloma Patients and Role of Second Salvage Transplant: a Single Center Prospective Phase Ii Study
Biology of Blood and Marrow Transplantation
2012

Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2012

Safety and Efficacy of Oral Azacitidine (Cc-486) Administered in Extended Treatment Schedules To Patients With Lower-Risk Myelodysplastic Syndromes
Blood
2012

Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: a Single Center Prospective Phase II Study- An Update
Blood
2012

Peripheral Blood Cd34(+) Specific Donor Chimerism Analysis as An Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndromes and Acute Myelogenous Leukemia.
Blood
2012

Oncolytic virotherapy for hematological malignancies.
Advances in virology
2012

Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study.
Transfusion
2012

Extended Dosing of Oral Azacitidine (Cc-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule
Blood
2012

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.
JAMA
2012

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.
JAMA
2012

Characteristics of thawed autologous umbilical cord blood.
Transfusion
2012

Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.
Journal of oncology
2012

Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro.
Leukemia research
2012

A Phase I Study of the Vascular Disrupting Combretastatin, Oxi4503, in Patients With Relapsed and Refractory Acute Myeloid Leukemia (Aml) and Myelodysplastic Syndromes (Mds)
Blood
2012

The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.
The Journal of biological chemistry
2011

The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Neoplasia (New York, N.Y.)
2011

Results From Latetime: a Randomized, Placebo Controlled Trial of Intracoronary Stem Cell Delivery Two To Three Weeks Following Acute Myocardial Infarction
Circulation
2011

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2011

Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.
Blood
2011

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.
JAMA
2011

Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.
Leukemia research
2011

Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale.
American heart journal
2011

Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.
Cytokine & growth factor reviews
2010

Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience.
Cytotherapy
2010

Leukemia regression by vascular disruption and antiangiogenic therapy.
Blood
2010

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
Texas Heart Institute journal
2010

Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.
American heart journal
2010

Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Clinical advances in hematology & oncology : H&O
2010

High Rate of Uncaptured Myelodysplastic Syndrome Cases At the State Cancer Registry Level
Blood
2010

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: a Phase I Study
Blood
2010

Acute Myeloid Leukemia Cells Depend On Vegf, Pdgfr and Scf Receptor Signaling: Leukemia Regression With Pazopanib
Blood
2010

Time From Onset of Acute Anterior Myocardial Infarction Negatively Influences Bone Marrow Cell Function: Preliminary Data From the Nhlbi Cctrn Ancillary Studies
Circulation
2009

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.
American heart journal
2009

Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells.
Leukemia
2009

Impact of Azacytidine Induction Chemotherapies On Post-Transplant Outcomes in Patients With Myelodysplastic Syndromes
Journal of Clinical Oncology
2009

Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge
Blood
2009

Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.
Blood
2009

Aml Regression By Vascular Disruption With Oxi4503 and Anti-Angiogenesis With Bevacizumab.
Blood
2009

Aldehyde dehydrogenase activity as a functional marker for lung cancer.
Chemico-biological interactions
2009

A Phase 1, Open-Label, Dose-Escalation Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients With Myelodysplastic Syndromes (Mds) Or Acute Myelogenous Leukemia (Aml)
Blood
2009

A Comparative Pharmacokinetic/Pharmacodynamic (Pk/Pd) Evaluation of Azacitidine Following Subcutaneous (Sc) and Oral Administration in Subjects With Myelodysplastic Syndromes (Mds) Or Acute Myelogenous Leukemia (Aml), Results From a Phase 1 Study
Blood
2009

Non-Myeloablative Allogeneic Stem Cell Transplantation To Treat High Risk Heavily Pretreated Multiple
Biology of Blood and Marrow Transplantation
2008

Marrow cell therapies for cardiovascular diseases.
Experimental hematology
2008

The hunt for cancer-initiating cells: a history stemming from leukemia.
Leukemia
2007

Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts.
Journal of leukocyte biology
2007

Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry.
Stem cells (Dayton, Ohio)
2007

The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells.
Journal of translational medicine
2006

Stem cell research.
Paediatric respiratory reviews
2006

Donor-derived type II pneumocytes are rare in the lungs of allogeneic hematopoietic cell transplant recipients.
Annals of clinical and laboratory science
2006

Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34.
Blood
2005

Developmental differences in megakaryocyte maturation are determined by the microenvironment.
Stem cells (Dayton, Ohio)
2005

Bone marrow-derived stem-cell repopulation contributes minimally to the Type II pneumocyte pool in transplanted human lungs.
Transplantation
2005

The hemangioblast: cradle to clinic.
Experimental hematology
2004

Bone marrow transdifferentiation in brain after transplantation: a retrospective study.
Lancet (London, England)
2004

Adult human hematopoietic cells provide functional hemangioblast activity.
Blood
2004

Typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia.
Clinical advances in hematology & oncology : H&O
2003

Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
American journal of hematology
2003

An overview of stem cell research and regulatory issues.
Mayo Clinic proceedings
2003

Research Interests

Christopher R. Cogle, M.D. is a physician and scientist with research focus on cancer and health policy. In his early career Dr. Cogle discovered that blood stem cells make blood vessels and used that biology to invent new therapeutics and diagnostics for people with cancer and heart disease. In his mid career, as a Leukemia & Lymphoma Society Scholar in Clinical Research, he began translating research discoveries into investigator-initiated clinical trials. Dr. Cogle has also made major discoveries in cancer epidemiology and was elected to lead Florida’s cancer prevention and control efforts at the state level, producing the Florida Cancer Plan, leading statewide campaigns for improved cancer prevention and control, and advising the Florida Legislature, Florida Secretary of Health, and Florida Governor on evidence-based strategies to reduce the state's cancer burden. In 2020, Dr. Cogle was selected by the National Academy of Medicine as an Emerging Leader in Health and Medicine Scholar. As a Scholar he works to increase access to high quality health care by studying and improving health policies of government entities and health systems.

Active Research Studies